Literature DB >> 11918866

The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis.

Stephen M Parnes1.   

Abstract

Leukotrienes are inflammatory mediators that are known as the slow-reacting substance of anaphylaxis produced by a number of cell types, including mast cells, eosinophils, basophils, macrophages, and monocytes. Synthesis of these meditators in the text result from the cleavage of arachidonic acid in cell membranes, and exert their biologic effects by binding and activating specific adaptors. This occurs in a serious of events that lead to contraction of the human airway smooth muscle, chemotaxis, and increased vascular permeability. These effects have lead to their important role in the diseases of asthma, allergic rhinitis, and possible paranasal sinusitis with the formation of nasal polyps. Since these agents lead to the production of symptoms in patients who are asthmatic, the use of leukotriene enzyme inhibitors, particularly montelukast, zafirlukasts seem appropriate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918866     DOI: 10.1007/s11882-002-0025-y

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  27 in total

1.  Eicosanoids from biopsy of normal and polypous nasal mucosa.

Authors:  H W Baenkler; D Schäfer; W Hosemann
Journal:  Rhinology       Date:  1996-09       Impact factor: 3.681

Review 2.  Antileukotrienes in the treatment of asthma.

Authors:  P M O'Byrne; E Israel; J M Drazen
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

3.  Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.

Authors:  B Knorr; J Matz; J A Bernstein; H Nguyen; B C Seidenberg; T F Reiss; A Becker
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

Review 4.  Treatment of asthma with drugs modifying the leukotriene pathway.

Authors:  J M Drazen; E Israel; P M O'Byrne
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

5.  Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

Authors:  B Dahlén; E Nizankowska; A Szczeklik; O Zetterström; G Bochenek; M Kumlin; L Mastalerz; G Pinis; L J Swanson; T I Boodhoo; S Wright; L M Dubé; S E Dahlén
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

6.  Aspirin intolerance in patients with chronic sinusitis.

Authors:  J Gosepath; F Hoffmann; D Schäfer; R G Amedee; W J Mann
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1999 May-Jun       Impact factor: 1.538

7.  Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.

Authors:  H R Knapp
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

Review 8.  Anti-leukotriene therapy in asthma.

Authors:  Z Diamant; E H Bel; P N Dekhuijzen
Journal:  Neth J Med       Date:  1998-10       Impact factor: 1.422

Review 9.  Therapeutic advances: leukotriene antagonists for the treatment of asthma.

Authors:  J Misson; W Clark; M J Kendall
Journal:  J Clin Pharm Ther       Date:  1999-02       Impact factor: 2.512

10.  Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.

Authors:  A R Fischer; M A Rosenberg; C M Lilly; J C Callery; P Rubin; J Cohn; M V White; Y Igarashi; M A Kaliner; J M Drazen
Journal:  J Allergy Clin Immunol       Date:  1994-12       Impact factor: 10.793

View more
  2 in total

Review 1.  Pharmacological management of nasal polyposis.

Authors:  Claus Bachert; Jean-Baptiste Watelet; Philippe Gevaert; Paul Van Cauwenberge
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Taurine promotes the production of CD4+CD25+FOXP3+ Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model.

Authors:  Jing Zhou; Yi Lu; Wei Wu; Yunhai Feng
Journal:  Allergy Asthma Clin Immunol       Date:  2021-06-19       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.